Decoy Therapeutics announced progress on its pan-coronavirus antiviral program, expecting to file for clinical trial approval in the second half of 2027. Their optimized lead candidate shows promise for once-weekly dosing, potentially improving patient adherence and reducing costs. The company is also exploring treatments for filoviruses like Ebola and seeking non-dilutive funding to support development. As of September 30, 2026, Decoy holds $8.1 million in cash, including Gates Foundation grant funds, to advance its pipeline.
Decoy Therapeutics' third quarter 2026 update comes as a backdrop to a mixed market day in the health sector. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 74 rose and 69 fell. Notable movers include AHCO (AdaptHealth Corp) at USD 6.20 with a 1-day change of +4.91% and a typical hold time on Pluang of 21 days, NUVB (Nuvation Bio Inc. Class A Common Stock) at USD 4.81 with a 1-day change of +4.79%, and ACB (Aurora Cannabis Inc) at USD 4.40 with a 1-day change of +4.27%.
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
